<DOC>
	<DOCNO>NCT01646281</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) associate decreased atrial contractility associate stroke . Decreased contractility become apparent cardioversion atrial fibrillation , short period ( week ) stroke risk increase . Improved contractility immediately cardioversion may prevent arrhythmia progression . In addition , may reduce stroke risk . Vernakalant new antiarrhythmic drug able convert atrial fibrillation sinus rhythm time increase atrial contractility . The latter yet show human subject present investigation . Our hypothesis human contractility atria high administration vernakalant compare flecainide . If indeed vernakalant improves atrial contractility cardioversion study effect long-term arrhythmia progression stroke prevention may follow .</brief_summary>
	<brief_title>Vernakalant Versus Flecainide : Atrial Contractility</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<criteria>persistent AF paroxysmal AF eligible treatment vernakalant flecainide infusion restore sinus rhythm receive adequate anticoagulant therapy ( episode AF last &lt; 24 hour ) refusal inability give inform consent participate study atrial flutter contraindication receive vernakalant flecainide accord MUMC+ protocol ( unstable hemodynamic condition , LVEF &lt; 40 % , inadequate potassium level , acute ischaemia , sinus node dysfunction ) age &lt; 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Vernakalant</keyword>
	<keyword>Flecainide</keyword>
	<keyword>Echocardiography</keyword>
</DOC>